NCT03865082 2022-02-17Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)Idera Pharmaceuticals, Inc.Phase 2 Active not recruiting30 enrolled